Handelen Takeda Pharmaceutical Company Limited - 4502 CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Spread | 24.12 | ||||||||
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.010938% | ||||||||
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | -0.011284% | ||||||||
Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
Min. verhandelde hoeveelheid | 1 | ||||||||
Valuta | JPY | ||||||||
Marge | 20% | ||||||||
Effectenbeurs | Japan | ||||||||
Handelscommissie | 0% |
*Information provided by Capital.com
Prev. Close* | 4252.6 |
Open* | 4228.56 |
1-Jaarlijkse Verandering* | 17.37% |
Dagelijks bereik* | 4228.56 - 4266.86 |
52 wekelijks bereik | 3,455.00-4,478.00 |
Weekgemiddelde volume (10 dagen) | 5.94M |
Gemiddeld volume (3 maanden) | 88.20M |
Marktkapitalisatie | 6,745.33B |
P/E Ratio | 24.23 |
Uitstaande Aandelen | 1.55B |
Omzet | 3,944.61B |
EPS | 175.97 |
Dividend (opbrengst %) | 4.22238 |
Beta | 0.99 |
Volgende inkomsten datum | May 11, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
---|---|---|---|---|---|---|
Mar 24, 2023 | 4254.99 | 11.77 | 0.28% | 4243.22 | 4267.86 | 4224.16 |
Mar 23, 2023 | 4252.60 | -32.31 | -0.75% | 4284.91 | 4286.90 | 4240.03 |
Mar 22, 2023 | 4358.72 | -55.75 | -1.26% | 4414.47 | 4414.47 | 4352.73 |
Mar 20, 2023 | 4283.82 | -61.23 | -1.41% | 4345.05 | 4347.74 | 4282.72 |
Mar 17, 2023 | 4369.09 | 34.51 | 0.80% | 4334.58 | 4382.66 | 4320.91 |
Mar 16, 2023 | 4273.94 | 6.88 | 0.16% | 4267.06 | 4292.79 | 4244.02 |
Mar 15, 2023 | 4332.19 | 30.12 | 0.70% | 4302.07 | 4332.19 | 4286.81 |
Mar 14, 2023 | 4265.46 | 32.02 | 0.76% | 4233.44 | 4293.29 | 4206.11 |
Mar 13, 2023 | 4279.92 | 5.49 | 0.13% | 4274.43 | 4290.30 | 4240.93 |
Mar 10, 2023 | 4335.78 | -9.97 | -0.23% | 4345.75 | 4354.23 | 4323.71 |
Mar 9, 2023 | 4388.64 | 54.76 | 1.26% | 4333.88 | 4390.64 | 4317.82 |
Mar 8, 2023 | 4323.81 | 31.92 | 0.74% | 4291.89 | 4329.90 | 4289.00 |
Mar 7, 2023 | 4289.10 | 19.16 | 0.45% | 4269.94 | 4292.89 | 4264.86 |
Mar 6, 2023 | 4260.97 | 21.94 | 0.52% | 4239.03 | 4269.45 | 4233.94 |
Mar 3, 2023 | 4237.04 | 46.28 | 1.10% | 4190.76 | 4252.40 | 4190.16 |
Mar 2, 2023 | 4172.11 | 5.49 | 0.13% | 4166.62 | 4188.56 | 4155.23 |
Mar 1, 2023 | 4165.22 | -5.09 | -0.12% | 4170.31 | 4191.16 | 4164.13 |
Feb 28, 2023 | 4195.54 | 28.22 | 0.68% | 4167.32 | 4201.53 | 4166.22 |
Feb 27, 2023 | 4186.07 | -13.37 | -0.32% | 4199.44 | 4211.11 | 4183.17 |
Feb 24, 2023 | 4186.07 | -49.07 | -1.16% | 4235.14 | 4235.14 | 4157.63 |
Takeda Pharmaceutical Company Limited Events
Tijd (UTC) (UTC) | Land | Evenement |
---|---|---|
No events scheduled |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Totale inkomsten | 3569010 | 3197810 | 3291190 | 2097220 | 1770530 |
Inkomsten | 3569010 | 3197810 | 3291190 | 2097220 | 1770530 |
Kosten van opbrengsten, totaal | 1106850 | 994308 | 1089760 | 651729 | 495921 |
Brutowinst | 2462160 | 2203500 | 2201420 | 1445500 | 1274610 |
Totale bedrijfskosten | 3123810 | 2596860 | 3193730 | 1874650 | 1531000 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 886361 | 875663 | 964737 | 717599 | 628106 |
Onderzoek & Ontwikkeling | 526087 | 455833 | 492381 | 368298 | 325441 |
Depreciation / Amortization | 472915 | 421864 | 455420 | 178617 | 122131 |
Ongebruikelijke uitgaven (inkomsten) | 100290 | -265230 | 189043 | -41201 | 28183 |
Other Operating Expenses, Total | 31309 | 114422 | 2384 | -2507 | -3907 |
Bedrijfsresultaat | 445198 | 600952 | 97459 | 222577 | 239528 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | -142628 | -234717 | -158213 | -94965 | -22323 |
Overige, Netto | 1 | ||||
Netto inkomen voor belastingen | 302571 | 366235 | -60754 | 127612 | 217205 |
Netto inkomen na belastingen | 230166 | 376171 | 44290 | 135080 | 186708 |
Minderheidsbelang | -107 | -166 | -49 | 112 | 178 |
Netto inkomen voor extra. Posten | 230059 | 376005 | 44241 | 135192 | 186886 |
Netto inkomen | 230059 | 376005 | 44241 | 135192 | 186886 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | 230059 | 376005 | 44241 | 135192 | 186886 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | 230059 | 376005 | 44241 | 135192 | 186886 |
Verwaterd Netto Inkomen | 230059 | 376005 | 44241 | 135192 | 186886 |
Verwaterd Gewogen Gemiddelde Aandelen | 1577.17 | 1573.54 | 1566.2 | 966.897 | 786.69 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | 145.868 | 238.955 | 28.2473 | 139.82 | 237.56 |
Dividends per Share - Common Stock Primary Issue | 180 | 180 | 180 | 180 | 180 |
Verwaterde Genormaliseerde Winst per Aandeel | 194.24 | 129.394 | 106.703 | 112.123 | 268.355 |
Rentekosten (inkomsten) - Operationeel nettobedrijfsresultaat | 2112 | -64872 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Totale inkomsten | 873289 | 901294 | 844819 | 949603 | 770274 |
Inkomsten | 873289 | 901294 | 844819 | 949603 | 770274 |
Kosten van opbrengsten, totaal | 308380 | 281404 | 275797 | 241264 | 253446 |
Brutowinst | 564909 | 619890 | 569022 | 708339 | 516828 |
Totale bedrijfskosten | 874908 | 784810 | 747392 | 701051 | 619734 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 223429 | 231078 | 212011 | 219843 | 234388 |
Onderzoek & Ontwikkeling | 143628 | 128378 | 131600 | 122480 | 113289 |
Depreciation / Amortization | 149283 | 118087 | 102721 | 102824 | 114294 |
Ongebruikelijke uitgaven (inkomsten) | 33062 | 26767 | 27979 | 16751 | 29440 |
Other Operating Expenses, Total | 17126 | -904 | -2716 | -2111 | -125123 |
Bedrijfsresultaat | -1619 | 116484 | 97427 | 248552 | 150540 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | -52429 | -44291 | -35980 | -25574 | -19662 |
Netto inkomen voor belastingen | -54047 | 72193 | 61447 | 222978 | 130878 |
Netto inkomen na belastingen | -11375 | 57820 | 45995 | 137726 | 197144 |
Minderheidsbelang | 17 | -51 | -31 | -43 | -46 |
Netto inkomen voor extra. Posten | -11358 | 57769 | 45964 | 137683 | 197098 |
Netto inkomen | -11358 | 57769 | 45964 | 137683 | 197098 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -11358 | 57770 | 45964 | 137684 | 197098 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -11358 | 57770 | 45964 | 137684 | 197098 |
Verwaterd Netto Inkomen | -11358 | 57770 | 45964 | 137684 | 197098 |
Verwaterd Gewogen Gemiddelde Aandelen | 1553.81 | 1574.97 | 1580.42 | 1574.43 | 1574.48 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -7.30976 | 36.68 | 29.0834 | 87.4503 | 125.183 |
Dividends per Share - Common Stock Primary Issue | 90 | 0 | 90 | 0 | 90 |
Verwaterde Genormaliseerde Winst per Aandeel | 6.52092 | 50.2916 | 42.335 | 94.0219 | 137.337 |
Total Adjustments to Net Income | 1 | 0 | 1 | ||
Overige, Netto | 1 |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Totaal vlottende activa | 2593640 | 2712890 | 2469430 | 2993040 | 1078810 |
Geldmiddelen en kortetermijnbeleggingen | 875000 | 1002820 | 653436 | 725819 | 375186 |
Geldmiddelen & Equivalenten | 389058 | 335027 | 188640 | 462890 | 243324 |
Korte Termijn Investeringen | 485942 | 667793 | 464796 | 262929 | 131862 |
Totale Vorderingen, Netto | 724377 | 812714 | 784921 | 749119 | 428792 |
Accounts Receivable - Trade, Net | 617518 | 707487 | 670708 | 657681 | 360833 |
Total Inventory | 853167 | 753881 | 759599 | 919670 | 212944 |
Other Current Assets, Total | 141098 | 143478 | 271476 | 598429 | 61886 |
Total Assets | 13178000 | 12912300 | 12821100 | 13792800 | 4106460 |
Property/Plant/Equipment, Total - Net | 1582800 | 1453920 | 1386370 | 1331930 | 536801 |
Property/Plant/Equipment, Total - Gross | 2453010 | 2191740 | 2084120 | 1971520 | 1191400 |
Accumulated Depreciation, Total | -870208 | -737818 | -697754 | -639591 | -654597 |
Goodwill, Net | 4407750 | 4033920 | 4012530 | 4240250 | 1029250 |
Intangibles, Net | 3818540 | 3909110 | 4171360 | 4751170 | 1014260 |
Long Term Investments | 330133 | 348350 | 369455 | 299922 | 304385 |
Other Long Term Assets, Total | 445150 | 454110 | 411948 | 176463 | 142957 |
Total Current Liabilities | 2145730 | 1773180 | 2175900 | 2553050 | 737509 |
Accounts Payable | 295933 | 232105 | 211627 | 212348 | 133705 |
Notes Payable/Short Term Debt | 285 | 69 | 5014 | 500002 | 18 |
Current Port. of LT Debt/Capital Leases | 203708 | 22084 | 581803 | 484944 | |
Other Current Liabilities, Total | 1645800 | 1518920 | 1377450 | 1355760 | 603786 |
Total Liabilities | 7495000 | 7739260 | 8097610 | 8610790 | 2109040 |
Total Long Term Debt | 4141420 | 4613220 | 4506490 | 4766000 | 985644 |
Long Term Debt | 4141420 | 4613220 | 4506490 | 4766000 | 985644 |
Deferred Income Tax | 473145 | 576542 | 765079 | 783356 | 90725 |
Minority Interest | 504 | 4140 | 4003 | 4006 | 19985 |
Other Liabilities, Total | 734202 | 772180 | 646144 | 504372 | 275176 |
Total Equity | 5683020 | 5173040 | 4723480 | 5181980 | 1997420 |
Common Stock | 1676260 | 1668140 | 1668120 | 1643580 | 77914 |
Additional Paid-In Capital | 1708870 | 1688420 | 1680290 | 1650230 | 90740 |
Retained Earnings (Accumulated Deficit) | 1479720 | 1509910 | 1369970 | 1595430 | 1557310 |
Treasury Stock - Common | -116007 | -59552 | -87463 | -57142 | -74373 |
Unrealized Gain (Loss) | 22068 | 41983 | 22891 | 46380 | 73037 |
Other Equity, Total | 912106 | 324131 | 69673 | 303499 | 272799 |
Total Liabilities & Shareholders’ Equity | 13178000 | 12912300 | 12821100 | 13792800 | 4106460 |
Total Common Shares Outstanding | 1550.36 | 1563.36 | 1557.77 | 1554.78 | 781.309 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Totaal vlottende activa | 2593640 | 2477890 | 2456350 | 2476460 | 2712890 |
Geldmiddelen en kortetermijnbeleggingen | 875000 | 751896 | 633623 | 684850 | 1002820 |
Geldmiddelen & Equivalenten | 849695 | 724341 | 607881 | 654920 | 966222 |
Korte Termijn Investeringen | 25305 | 27555 | 25742 | 29930 | 36598 |
Totale Vorderingen, Netto | 724377 | 756117 | 887295 | 858957 | 812714 |
Accounts Receivable - Trade, Net | 696644 | 715515 | 843625 | 827253 | 783091 |
Total Inventory | 853167 | 811324 | 783476 | 779148 | 753881 |
Other Current Assets, Total | 141098 | 158556 | 151959 | 153503 | 143478 |
Total Assets | 13178000 | 12698500 | 12560300 | 12657200 | 12912300 |
Property/Plant/Equipment, Total - Net | 1582800 | 1493590 | 1459920 | 1452170 | 1453920 |
Goodwill, Net | 4407750 | 4167990 | 4078370 | 4058940 | 4033920 |
Intangibles, Net | 3818540 | 3791880 | 3783680 | 3856430 | 3909110 |
Long Term Investments | 330133 | 334812 | 352091 | 374659 | 348350 |
Other Long Term Assets, Total | 445150 | 432359 | 429864 | 438578 | 454110 |
Total Current Liabilities | 2145730 | 1809250 | 1918750 | 1706780 | 1773180 |
Accounts Payable | 516297 | 351185 | 336600 | 320645 | 343838 |
Notes Payable/Short Term Debt | 285 | 0 | 0 | 0 | 69 |
Current Port. of LT Debt/Capital Leases | 203708 | 122936 | 214886 | 24272 | 22084 |
Other Current Liabilities, Total | 1425440 | 1335130 | 1367260 | 1361860 | 1407180 |
Total Liabilities | 7495000 | 7367190 | 7236340 | 7418980 | 7739260 |
Total Long Term Debt | 4141420 | 4231940 | 4016470 | 4381590 | 4613220 |
Long Term Debt | 4141420 | 4231940 | 4016470 | 4381590 | 4613220 |
Deferred Income Tax | 473145 | 589481 | 576738 | 578065 | 576542 |
Minority Interest | 504 | 493 | 426 | 385 | 4140 |
Other Liabilities, Total | 734202 | 736023 | 723951 | 752155 | 772180 |
Total Equity | 5683020 | 5331330 | 5323940 | 5238260 | 5173040 |
Common Stock | 1676260 | 1676260 | 1676260 | 1669120 | 1668140 |
Additional Paid-In Capital | 1708870 | 1697560 | 1686490 | 1682500 | 1688420 |
Retained Earnings (Accumulated Deficit) | 1479720 | 1466930 | 1551150 | 1503810 | 1509910 |
Treasury Stock - Common | -116007 | -91013 | -41037 | -42344 | -59552 |
Unrealized Gain (Loss) | 22068 | 31196 | 57646 | 41983 | |
Other Equity, Total | 912106 | 550395 | 451066 | 367516 | 324131 |
Total Liabilities & Shareholders’ Equity | 13178000 | 12698500 | 12560300 | 12657200 | 12912300 |
Total Common Shares Outstanding | 1550.36 | 1557.49 | 1572.83 | 1568.66 | 1563.36 |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Netto-inkomen/Beginsaldo | 230166 | 376171 | 44290 | 109014 | 186708 |
Geldmiddelen uit Operationele Activiteiten | 1123100 | 1010930 | 670381 | 328301 | 399200 |
Geldmiddelen uit Operationele Activiteiten | 583151 | 559671 | 583649 | 272446 | 182127 |
Niet-Geldelijke Posten | 252109 | 12308 | 172928 | 39061 | -43306 |
Cash Taxes Paid | 140423 | 201687 | 226768 | 44909 | 29883 |
Contant Betaalde Rente | 108207 | 107350 | 127211 | 34914 | 8365 |
Veranderingen in het Operationeel Kapitaal | 57679 | 62781 | -130486 | -92220 | 73671 |
Geldmiddelen uit Investeringsactiviteiten | -198125 | 393530 | 292119 | -2835700 | -93342 |
Kapitaaluitgaven | -186037 | -236468 | -217710 | -134114 | -128262 |
Overige Cash Flow investeringsposten, Totaal | -12088 | 629998 | 509829 | -2701580 | 34920 |
Geldmiddelen uit Financieringsactiviteiten | -1070260 | -1088350 | -1005210 | 2946240 | -326226 |
Financiering van Cash Flow Posten | -108592 | -142352 | -132804 | -71143 | -15099 |
Total Cash Dividends Paid | -283665 | -283357 | -282582 | -142952 | -141893 |
Uitgifte (Aflossing) van aandelen, netto | -77531 | -2141 | -3737 | -1172 | -18756 |
Uitgifte (Aflossing) van Schulden, Netto | -600477 | -660504 | -586090 | 3161500 | -150478 |
Wisselkoerseffecten | 28758 | 12501 | -21766 | -31269 | -4565 |
Nettowijziging in Geldmiddelen | -116527 | 328608 | -64479 | 407571 | -24933 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | 230166 | 241541 | 183721 | 137726 | 376171 |
Cash From Operating Activities | 1123100 | 747521 | 400011 | 166858 | 1010930 |
Cash From Operating Activities | 583151 | 430877 | 283595 | 142948 | 559671 |
Non-Cash Items | 252109 | 187026 | 112596 | 53003 | 12308 |
Cash Taxes Paid | 140423 | 101086 | 73872 | 35902 | 201687 |
Cash Interest Paid | 108207 | 84917 | 52668 | 23218 | 107350 |
Changes in Working Capital | 57679 | -111923 | -179901 | -166819 | 62781 |
Cash From Investing Activities | -198125 | -172487 | -103349 | -70445 | 393530 |
Capital Expenditures | -186037 | -134214 | -85783 | -42292 | -236468 |
Other Investing Cash Flow Items, Total | -12088 | -38273 | -17566 | -28153 | 629998 |
Cash From Financing Activities | -1070260 | -826465 | -658405 | -411038 | -1088350 |
Financing Cash Flow Items | -108592 | -85284 | -52681 | -23218 | -142352 |
Total Cash Dividends Paid | -283665 | -273024 | -141573 | -132032 | -283357 |
Issuance (Retirement) of Stock, Net | -77531 | -52538 | -2542 | -2542 | -2141 |
Issuance (Retirement) of Debt, Net | -600477 | -415619 | -461609 | -253246 | -660504 |
Foreign Exchange Effects | 28758 | 9549 | 3402 | 3324 | 12501 |
Net Change in Cash | -116527 | -241882 | -358341 | -311301 | 328608 |
Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
---|---|---|---|---|---|---|
Nomura Asset Management Co., Ltd. | Investment Advisor | 4.1084 | 65007007 | -76000 | 2023-02-28 | LOW |
Sumitomo Mitsui Trust Asset Management Co., Ltd. | Investment Advisor | 3.8571 | 61030834 | 60935676 | 2022-11-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.6684 | 42222686 | 45800 | 2023-02-28 | LOW |
JPMorgan Securities Japan Co., Ltd. | Research Firm | 2.3848 | 37735000 | 13609000 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.2311 | 35302592 | -811008 | 2023-02-28 | LOW |
Nikko Asset Management Co., Ltd. | Investment Advisor/Hedge Fund | 2.0544 | 32507000 | 2470629 | 2022-11-30 | LOW |
Daiwa Asset Management Co., Ltd. | Investment Advisor | 1.8823 | 29784238 | -48400 | 2023-02-28 | LOW |
Nippon Life Insurance Company | Insurance Company | 1.861 | 29447000 | -2377000 | 2022-09-30 | LOW |
Capital Research Global Investors | Investment Advisor | 1.8554 | 29358500 | 18800 | 2023-01-31 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.5239 | 24113047 | 1171849 | 2022-12-31 | LOW |
Takeda Science Foundation | Corporation | 1.132 | 17912000 | 0 | 2022-09-30 | LOW |
Mitsubishi UFJ Kokusai Asset Management Co., Ltd. | Investment Advisor | 0.778 | 12309837 | -65791 | 2023-02-28 | LOW |
CPP Investment Board | Pension Fund | 0.7341 | 11616000 | 7985000 | 2022-03-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7089 | 11216737 | 13283 | 2023-02-28 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 0.5202 | 8230678 | 143900 | 2023-02-28 | LOW |
BlackRock Asset Management Ireland Limited | Investment Advisor | 0.5143 | 8137797 | 8137597 | 2021-06-30 | LOW |
M & G Investment Management Ltd. | Investment Advisor | 0.4559 | 7213600 | 0 | 2023-01-31 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.4421 | 6994953 | 16400 | 2023-02-28 | LOW |
DWS Investment GmbH | Investment Advisor/Hedge Fund | 0.4359 | 6897836 | -59516 | 2023-02-28 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.4172 | 6601449 | 10924 | 2023-01-31 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group500K+
Handelaren
92K+
Actieve klanten per maand
$53M+
Maandelijks beleggingsvolume
$30M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Takeda Pharmaceutical Company Limited Company profile
Over Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited is een in Japan gevestigde onderneming die zich voornamelijk bezighoudt met de farmaceutische sector. De onderneming houdt zich bezig met onderzoek, ontwikkeling, vervaardiging en verkoop van farmaceutische producten, algemene medische producten, quasi-geneesmiddelen en gezondheidsproducten in Japan en overzee. De onderzoeks- en ontwikkelingsfuncties van het bedrijf zijn geconcentreerd op vier gebieden: oncologie (kanker), ziekten van het spijsverteringsstelsel, zeldzame ziekten en neurologie (neuropsychiatrische ziekten), alsmede twee bedrijfseenheden voor plasmafractioneringsproducten en vaccins. De Onderneming houdt zich bezig met de verbetering van de pijplijnen in onderzoeks- en ontwikkelingscentra die zich hoofdzakelijk in Japan en de Verenigde Staten bevinden.
Industry: | Pharmaceuticals (NEC) |
4階
日本橋本町二丁目1番1号
CHUO-KU
TOKYO-TO 103-8668
JP
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 500.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen